Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 40, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-13
DOI
10.1186/s13046-021-02043-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Arginine Metabolism and Its Potential in Treatment of Colorectal Cancer
- (2021) Tao Du et al. Frontiers in Cell and Developmental Biology
- Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
- (2020) Wenyan Zhong et al. BMC GENOMICS
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Supplementation of L‐arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy
- (2020) Yusuke Satoh et al. CANCER SCIENCE
- Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
- (2020) Lei Zhang et al. CELL
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- Macrophages and Metabolism in the Tumor Microenvironment
- (2019) Ilio Vitale et al. Cell Metabolism
- Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression
- (2018) Dewan Md Sakib Hossain et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
- (2018) Mirjana Efremova et al. Nature Communications
- Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases
- (2018) Pooja Dhupkar et al. Cancer Medicine
- Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
- (2018) Sun-Hee Kim et al. Frontiers in Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
- (2018) Howard L. Kaufman et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice
- (2018) Tanios Bekaii-Saab et al. Clinical Colorectal Cancer
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer
- (2016) Neil H. Segal et al. Clinical Colorectal Cancer
- Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
- (2016) Dieter Zopf et al. Cancer Medicine
- Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
- (2015) Hung Huynh et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Colorectal cancer
- (2015) Ernst J. Kuipers et al. Nature Reviews Disease Primers
- Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
- (2014) John C Castle et al. BMC GENOMICS
- Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
- (2014) Peter J. Murray et al. IMMUNITY
- Deciphering and Reversing Tumor Immune Suppression
- (2013) Greg T. Motz et al. IMMUNITY
- Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
- (2013) Roberta Schmieder et al. INTERNATIONAL JOURNAL OF CANCER
- Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
- (2013) L. Abou-Elkacem et al. MOLECULAR CANCER THERAPEUTICS
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started